Back to search results

Research Study on UBT251 for Overweight or Obesity

This study is looking at how well different doses of the medicine UBT251 help people who are living with overweight or obesity. You would receive either UBT251 or a placebo (a treatment with no active medicine) by injection under the skin. The study aims to see if UBT251 is safe and effective. Success will be measured by tracking any side effects and changes in body weight. We are also studying how UBT251 moves through the body. This study is currently recruiting about 333 participants between 18 and 65 years old.

Study design
This is an interventional study where participants are randomly assigned to receive either UBT251 or a placebo. Approximately 333 people are planned to enroll.
What's involved
You would receive UBT251 or placebo injections under the skin. The study measures side effects from baseline to week 33, and body weight changes from baseline to week 28. Drug levels are measured from Day 1 until the end of study visit on Day 43.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for treatment emergent adverse events (side effects) until the end of the study at week 33.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07395687

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Recruiting
PHASE2Ages 18–65InterventionalTreatment
Novo Nordisk A/S
~333 participants
Updated 2026-04-21 on ClinicalTrials.gov
What's tested:UBT251Placebo

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A - Number of treatment emergent adverse events (TEAEs)
Measured over From baseline (week 0) to end of study (week 33)
+2 more outcomes measured

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

3 sites across 3 states
California1
Kansas1
Quebec1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

For Japanese participants: both parents of Japanese descent.
For Chinese participants: both parents of Chinese descent.
For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia). 3. Age at the time of signing the informed consent:

What this trial measures

  • Part A - Number of treatment emergent adverse events (TEAEs)From baseline (week 0) to end of study (week 33)

    Measured as Number of events.

  • Part B - Relative change in body weightFrom baseline (week 0) to end of treatment (week 28)

    Measured as percentage of body weight.

  • Part C- AUC; the area under the UBT251 plasma concentration time curveFrom pre-dose on Day 1 until completion of the end of study visit (Day 43)

    Measured as hour\*nanomoles per liter (h\*nmol/L)